Pardes Biosciences, Inc. (PRDS): Price and Financial Metrics


Pardes Biosciences, Inc. (PRDS): $1.83

0.12 (+7.02%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PRDS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PRDS Stock Price Chart Interactive Chart >

Price chart for PRDS

PRDS Price/Volume Stats

Current price $1.83 52-week high $13.01
Prev. close $1.71 52-week low $0.75
Day low $1.66 Volume 401,250
Day high $1.94 Avg. volume 228,324
50-day MA $1.43 Dividend yield N/A
200-day MA $3.14 Market Cap 112.97M

Pardes Biosciences, Inc. (PRDS) Company Bio


Pardes Biosciences, Inc., a pre-clinical stage biotechnology company, engages in developing oral direct acting antivirals. Its antivirals target viral main cysteine protease, an essential viral protein required for coronaviruses to replicate. Pardes Biosciences, Inc. was incorporated in 2020 and is based in Carlsbad, California.


PRDS Latest News Stream


Event/Time News Detail
Loading, please wait...

PRDS Latest Social Stream


Loading social stream, please wait...

View Full PRDS Social Stream

Latest PRDS News From Around the Web

Below are the latest news stories about PARDES BIOSCIENCES INC that investors may wish to consider to help them evaluate PRDS as an investment opportunity.

Pardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Phase 2 trial evaluating PBI-0451 for treatment of COVID-19 ongoing, with data expected in first quarter of 2023CARLSBAD, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug candidate for the treatment and prevention of COVID-19 in adult and pediatric patients, today reported financial results for the third quarter ended September 30, 2022 and provided a business

Yahoo | November 7, 2022

Pardes Biosciences to Present at Jefferies London Healthcare Conference

CARLSBAD, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 8:00 a.m. GMT / 12:00 a.m

Yahoo | November 1, 2022

Pardes Biosciences Appoints Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to Board of Directors

CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and COVID-19 disease, today announced the appointments of Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to its Board of Directors. “As we advance PBI-0451 into a Phase 2 study, I am delighted to welcome both

Yahoo | September 14, 2022

Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 Infections

Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral activity, safety, and efficacy of PBI-0451 versus placebo Interim data from Phase 2 anticipated in Q1 2023 CARLSBAD, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and a

Yahoo | September 13, 2022

Pardes Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

CARLSBAD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), today announced that management will participate in a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2

Yahoo | September 12, 2022

Read More 'PRDS' Stories Here

PRDS Price Returns

1-mo 28.87%
3-mo 46.40%
6-mo -35.11%
1-year -83.09%
3-year N/A
5-year N/A
YTD 8.28%
2022 -89.68%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.765 seconds.